Pulmonary arterial hypertension (PAH) is a chronic progressive disease characterized by elevated pulmonary arterial pressure and vascular resistance. It often leads to severe, life-threatening conditions such as heart failure and premature death. Specific therapies can temporarily manage PAH, but their long-term benefits are unclear. Patients who have an inadequate response or are refractory to conventional medical treatments are considered for double lung or heart-lung transplants. However, the waitlist counters this process.
A lung allocation score reduces the waiting time and ensures that organs would go to those in most need. For more insights on the indications, contraindications, and management of PAH, we have Dr. Basha Khan and Dr. Prashant Bobhate joining us for an enlightening session on “Transplant and Pulmonary Hypertension” on 1 st November, 3:00 PM IST onwards. …
